** Shares of cancer drugmaker Exelixis EXEL.O fall 2.3% to $36.83
** US FDA approved EXEL's cancer drug, Cabometyx, for treating adult and pediatric patients with previously treated advanced neuroendocrine tumors $(NET)$
** Citizens Bank analyst Silvan Tuerkcan notes EXEL's shares declined as investors had already factored the approval into the stock price
** Tuerkcan says investor focus will now be on the launch of the drug for patients with NET, and size of the opportunity, which is expected to drive "a significant portion" of the company's sales growth in the near term
** Leerink Partners analyst Andrew Berens estimates Cabometyx to bring in $75 million for NET in 2025, with peak sales reaching $750 million before losing exclusivity impact starting in 2030
** Stock gained ~59% in the last 12 months
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。